Whether or not FFAR4 agonists prove to be compounds capable of limiting atherosclerosis by altering the phenotype of cells responsible for maintaining inflammation in the vessel wall remains an attractive hypothesis to be tested. The gene discussed is FFAR4; the disease is atherosclerosis.